Characteristics and Prospects for Hepatitis C Therapy of an HIV-HCV Coinfected Population Followed at a Reference HIV Center

REFERENCES

• Di Martino V, Rufat P, Boyer N, et al. The influence of HIV coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 200134: 1193–1199.
   Google Scholar
• Mohsen A, Easterbrook P, Taylor C, et al. Impact of HIV infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut. 2003;52:1035–1040.
   PubMed Web of Science ®Google Scholar
• Bice I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis. 2001;32:492–497.
   PubMed Web of Science ®Google Scholar
• Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing im-pact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retro viruses. 2001;17:1467–1472.
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803–1809.
   PubMed Web of Science ®Google Scholar
• Pérez-Olmeda M, Nuflez M, Garcia-Samaniego J, Romero M, Martin-Carbonero L, Soriano V. Pegylated interferon alpha 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17:1023–1028.
   PubMed Web of Science ®Google Scholar
• Chung R, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin vs interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–459.
   PubMed Web of Science ®Google Scholar
• Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450.
   PubMed Web of Science ®Google Scholar
• Garret F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA. 2004;292:2839–2848.
   PubMed Web of Science ®Google Scholar
• Laguno M, Murillas J, Blanco J, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2 b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27–F36.
   PubMed Web of Science ®Google Scholar
• Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18:1–12.
   PubMed Web of Science ®Google Scholar
• Pérez-Olmeda M, Rios P, Nuflez M, Garcia-Samaniego J, Romero M, Soriano V. Virological characteristics of hepati-tis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. AIDS. 200216: 493–495.
   Google Scholar
• Garcia-Benayas T, Blanco F, Soriano V. Weight loss in HIV-infected patients. N Engl J Med. 2002;347:1287–1288.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Consensus Development Conference: management of hepatitis C. Final statement. Gastroenterology. 2002123: 2082–2099.
   Google Scholar
• Stark K, Schreier E, Muller R, Wirth D, Driesel G, Bienzle U. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis. 1995;27:331–337.
   PubMed Web of Science ®Google Scholar
• Vitale F, Villafrate M, Viviano E, et al. Distribution of hepati-tis C virus genotypes among intravenous drug users. A ten-year study in Palermo, Sicily. New MicrobioL 1998;21:335–342.
   PubMed Web of Science ®Google Scholar
• Bonacini M, Govindarajan S, Black L, Schmid P, Conrad A, Lindsay K. Patients co-infected with HIV and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral HepaL 1999;6:203–208.
   PubMed Web of Science ®Google Scholar
• Franchini M, Rossetti G, Tagliaferri A, et al. The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood. 200198:1836–1841.
   Google Scholar
• Rai R, Wilson L, Astemborski J, et al. Severity and corre-lates of liver disease in hepatitis C virus-infected injection drug users. Hepatology. 2002;35:1247–1255.
   PubMed Web of Science ®Google Scholar
• Sherman K, Rouster S, Chung R, Rajicic N. Hepatitis C virus prevalence among patients infected with HIV: a cross-sectional analysis of the US ACTG. Clin Infect Dis. 2002;34:831–837.
   PubMed Web of Science ®Google Scholar
• Fleming C, Craven D, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and HIV coinfection in an urban popula-tion: low eligibility for interferon treatment. Clin Infect Dis. 2003;36:97–100.
   PubMed Web of Science ®Google Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV, et al. The preva-lence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556–562.
   PubMed Web of Science ®Google Scholar
• Kenny-Walsh E. Clinical outcomes after hepatitis C infec-tion from contaminated anti-D immune globulin. N Engl J Med. 1999;340:1228–1233.
   PubMed Web of Science ®Google Scholar
• Piasecki B, Lewis J, Reddy K, et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology. 2004;40:892–899.
   PubMed Web of Science ®Google Scholar
• Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clear-ance. Gut. 2004;53:1673–1681.
   PubMed Web of Science ®Google Scholar
• Buffet-Janvresse C, Peigue-Lafeuille H, Benichou J, et al. HIV and HCV co-infection: situation at six French university hospitals in the year 2000. J Med ViroL 2003;69:7–17.
   PubMed Web of Science ®Google Scholar
• Fultz S, Justice A, Butt A, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with HIV infection. Clin Infect Dis. 2003;36:1039–1046.
   PubMed Web of Science ®Google Scholar
• Rauch A, Egger M, Reichen J, Furrer H, and the Swiss HIV Cohort Study. Chronic hepatitis C in HIV-infected patients: low elegibility and applicability of therapy with pegylated interferon-a plus ribavirin. J Acquir Immune Defic Syndr. 2005;38:238–240.
   PubMed Web of Science ®Google Scholar
• Restrepo A, Johnson T, Widjaja D, et al. The rate of treat-ment of chronic hepatitis C in patients coinfected with HIV in an urban medical centre. J Viral Hepatitis. 2005;12:86–90.
   PubMed Web of Science ®Google Scholar
• Butt A, Wagener M, Shakil A, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepati-tis. 2005;12:81–85.
   PubMed Web of Science ®Google Scholar
• Mayers R, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004;18:75–79.
   PubMed Web of Science ®Google Scholar
• Thomas D, Shih J, Alter H, et al. Effect of HIV on hepatitis C virus infection among injecting drug users. J Infect Dis. 1996;174:690–695.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Fukuda Y, Nakano I, et al. Poor response to interferon treatment for chronic hepatitis C in HIV-infected haemophiliacs. Haemophilia. 2000;677–681.
   PubMed Web of Science ®Google Scholar
• Kuehne F, Bethe U, Freedberg K, Go!die S. Treatment for hepatitis C virus in HIV-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002;162:2545–2556.
   PubMed Web of Science ®Google Scholar
• Uberti-Foppa C, De Bona A, Morsica G, et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;33:146–152.
   PubMed Web of Science ®Google Scholar
• Puoti M, Torti C Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr. 2003;32:259–267.
   PubMed Web of Science ®Google Scholar
• Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Bassetti D. Rapid decline of CD4+ cells after IFN-alfa treat-ment in HIV-1 infection. Lancet. 1993;341:958–959.
   PubMed Web of Science ®Google Scholar
• Pesce A, TailIan B, Rosenthal E, et al. Opportunistic infec-tions and CD4 lymphocytopenia with interferon treatment in HIV-1-infected patients. Lancet. 1993;341:1597.
   PubMed Web of Science ®Google Scholar
• Soriano V, Garcfa-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. Hepatitis-HIV Spanish Study Group. Clin Infect Dis. 1996;23:585–591.
   PubMed Web of Science ®Google Scholar
• Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection. 1998;26:16–19.
   PubMed Web of Science ®Google Scholar
• Fried M. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(suppl):237–244.
   Google Scholar